QR Pharma is a specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
Posiphen reduces levels of amyloid precursor protein (APP), tau and α-Synuclein (aSYN), three proteins that can turn toxic and precipitate the onset of AD and PD. Posiphen inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans.
AD and PD affect more than 30 million people worldwide and is expected to grow to more than 120 million by 2050. The economic burden and impact on wellness and quality of life for both patients and their caregivers is crushing. Today, existing drugs manage the symptoms and provide only marginal cost-benefit tradeoffs. Therefore, it is imperative to bring drugs to market that stop the progression of these diseases.